CRP is an acute phase protein, and both the Centers for Disease Control and Prevention (CDC) and American Heart Association (AHA) have indicated that both average‐risk (1–3 mg/L), and high‐risk (> 3 mg/L) serum high‐sensitivity CRP (hs‐CRP) levels [6] are associated with significantly higher risk of cardiovascular death, myocardial infarction (MI), or stroke in stable patients with stable coronary artery disease, irrespective of coronary intervention, baseline characteristics or treatment arm, in a randomized setting [7]. Here, MAP3K14 is linked to myocardial infarction.